Zeposia (Ozanimod)
- Medicine Name: Zeposia
- Generic Name: Ozanimod
- Dosage Form & Strength: Capsules: 0.23 mg, 0.46 mg, 0.92 mg
- Manufactured By: Celgene Corporation
Medical uses
Warning & Precautions
Documentation & Availability
Sourcing & Delivery
FAQ
Medical uses
Zeposia is a sphingosine 1-phosphate receptor modulator used for the treatment of adults with:
- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing remitting disease, and active secondary progressive disease.
- Moderately to severely active ulcerative colitis (UC).
Recommended Dosage: Initiate treatment with a 7-day titration. The recommended initial dosage on Days 1-4 is 0.23 mg once daily, and on Days 5-7 is 0.46 mg once daily. After the initial titration, the recommended dosage is 0.92 mg taken by mouth (orally) once daily starting on Day 8. Swallow the zeposia capsules whole, with or without a meal. If a dose is missed during the initial 2 weeks of treatment, reinitiate treatment using the titration regimen. If a dose is missed after the initial 2 weeks of treatment, continue with the treatment as scheduled.
Warning & Precautions
- Ozanimod causes a mean reduction in peripheral blood lymphocyte count to around 45% of baseline values. Obtain a recent (i.e., within six months or after interruption of prior MS/UC therapy) CBC including lymphocyte count prior to initiation of Ozanimod 0.92 mg.
- Ozanimod may increase the susceptibility to infections, some serious in nature. Rare fatal and life-threatening infections have occurred in patients receiving Ozanimod. Delay initiation of Ozanimod in patients with an active infection until the infection is resolved.
- Ozanimod increased the probability of viral upper respiratory tract infections, herpes infections and urinary tract infections. Consider interruption of treatment with Ozanimod 0.23 mg or with any other dosage strength in case a patient develops a serious infection.
- Cases of fatal CM (cryptococcal meningitis) and disseminated cryptococcal infections have been noted with S1P receptor modulators. Doctors should be vigilant for clinical signs/symptoms of CM. Patients with signs/symptoms consistent with a cryptococcal infection need to undergo quick diagnostic assessment and treatment.
- A complete course of vaccination for antibody -Ve patients with varicella vaccine is recommended before commencing treatment with Ozanimod 0.46 mg or any other dosage strength, following which initiation of treatment with Ozanimod needs to be postponed for four weeks to allow the complete effect of vaccination to occur.
- Varicella zoster meningitis and herpes simplex encephalitis have been reported with sphingosine 1-phosphate (S1P) receptor modulators. Patients without a doctor-confirmed history of varicella (chickenpox), or without documentation of a full course of vaccination against varicella zoster virus (VZV), need to be tested for antibodies to VZV prior to initiating Zeposia 0.96 or any other dosage strength.
- Immune-modulating, anti-neoplastic or immunosuppressive therapies (including corticosteroids) need to be co-administered with caution due to the risk of additive immune system effects while on such therapy. When switching to Ozanimod from immunosuppressive medicines, consider the duration of their effects and their mode of action for avoiding unintended additive immunosuppressive effects.
- Since the zeposia uses may result in a transient reduction in heart rate and atrioventricular conduction delays, an up-titration scheme should be used in order to reach the maintenance dose of zeposia.
Documentation & Availability
What documents are required to import ZEPOSIA to India?
ZEPOSIA (Ozanimod) capsules can be imported by patients or government hospitals on the name of the patients only.
The following documentation required to import the product:
- Valid prescription from a qualified doctor.
- Patients diagnostic reports
- Patients id proof (issued by government of India)
How does order be confirmed?
The order will be confirmed only after the receipt of:
- Valid prescription of Doctor
- Import permit if applicable
Is ZEPOSIA available in India?
ZEPOSIA (ozanimod capsules) is a (prescription drug, prescription medication or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.
IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is facilitator providing input
- On availability in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore and Pune etc.)
- Medicine Price.
- Finding Genuine and reliable source from Canada, Europe, USA and Australia
- Ensuring 100% transparency.
ZEPOSIA can be made available to patients, doctors and hospitals at Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and import permit.
IPN (Indian Pharma Network) can facilitate the supply of ZEPOSIA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable)
Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@indianpharmanetwork.in for zeposia price in India.
We take guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.
Sourcing & Delivery
Indian Pharma Network is able to source the ZEPOSIA (Cancer Treatment Medicines) from across the globe, and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.
Indian Pharma Network is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.
FAQ
What is the Generic Name for the trade name drug Zeposia®?
Ozanimod is Generic Name for the trade name drug Zeposia®.
What is the Manufacturer Name of Zeposia®?
Zeposia® is manufactured by Celgene Corporation.
Is Zeposia® approved by the FDA?
Yes, Zeposia® is approved by the FDA. Date of approval: March 25, 2020.
What is Zeposia®?
Zeposia® (ozanimod) is a prescription medicinal product aimed to treat relapsing forms of multiple sclerosis (MS), and moderately to severely active ulcerative colitis (UC).
What is the dosage and form of Zeposia® supplied?
Zeposia® is supplied as Capsules: 0.23 mg, 0.46 mg, 0.92 mg for oral administration.
What are the most common side effects due to Zeposia®?
Most common side effects due to Zeposia® include: Multiple Sclerosis: hepatic transaminase elevation, upper respiratory infection, orthostatic hypotension, back pain, urinary tract infection, and hypertension.
Ulcerative Colitis: upper respiratory infection, liver test increased, and headache.
How much does Ozanimod cost in India?
The ozanimod cost in India is reasonably low. In order to procure this medicine for multiple sclerosis (MS) and ulcerative colitis (UC) authentically, call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.
What are the storage conditions of Zeposia®?
Store the capsules of Zeposia at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C to 30°C (59°F to 86°F).
What are the Highlights of prescribing information for Zeposia®?
Click Here to download full zeposia prescribing information.
Contact Patient Support
If you have any questions or need any help, contact our Patient Support Team. We will get in touch with you within 24 hours from Monday to Friday between 9:00 and 10:00 CET.
Disclaimer
CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis. CMV retinitis is kind of an eye infection caused by a virus. CMV mainly attacks the retina of the eye and can be responsible for causing loss of vision, and eventually may lead to the blindness. Patients with acquired immunodeficiency syndrome are more likely to develop CMV retinitis.